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ABSTRACT

Motivational alterations in HIV-1+ individuals are associated with decreased
performance on tasks involving frontal-subcortical circuitry and the nucleus
accumbens. In the present study, the HIV-1 transgenic (Tg) rat was used to
assess long-term HIV-1 viral protein exposure on motivated behavior using
activity chambers (40x40cm) and voluntary wheel running. Adult ovariectomized
female HIV-1 Tg animals (n=21) to F344 controls (n=26) were pair-housed under
a 12:12 light/dark cycle. Voluntary running was measured with 34 cm-diameter
running wheels for ~60 minutes/day for 3 ½ months. There were no significant
differences between HIV-1 Tg and F344 control rats in voluntary wheel running
during the light phase. Animals were subsequently run in the nocturnal phase of
their light/dark cycle. The F344 controls continued to escalate their overall
running distances and surpassed the stabilized HIV-1 Tg group after ~4 weeks of
nocturnal running, until reaching their asymptotic plateau at week 11. Neither
maximal running speed, nor the latency to initiate running or running bout length
were significantly different between groups. However, the groups were different
in the number of running bouts per session, as a function of the HIV-1 transgene.
Collectively, the selective alterations in the motivation for voluntary wheel running
and activity chamber locomotor activity, suggests a disruption of the motivational
circuitry within the HIV-1 Tg rat brain. Examination of Medium Spiny Neurons of
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the nucleus accumbens showed significant alterations in dendritic spine length
and spine head diameter. Further study of these alterations in spine parameters
may help elucidate the mechanisms of motivational alterations in HIV1+individuals.
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CHAPTER 1
INTRODUCTION
HIV-1 infection continues to increase in global prevalence despite
continued public education regarding HIV-1. As of 2015, approximately 37 million
individuals worldwide were infected with the virus, according to the World Health
Organization (World Health Organization, 2015). Since the advent of antiretroviral therapies (ART), virally-mediated mortality and quality-of-life has been
improved in seropositive individuals. Yet, despite the improvement in disease
pathology, the prevalence of the HIV-associated-neurocognitive disorders
(HAND) has remained stable globally throughout the pre-ART and post-ART eras
(Heaton et al., 2010; Heaton et al., 2011; Heaton et al., 2015; McArthur, Steiner,
Sacktor, & Nath, 2010; Watkins & Treisman, 2015). Within the realm of cognitive
impairments, reduced motivation is prevalent in ~50% of HIV-1 seropositive
individuals (Castellon, Hinkin, & Myers, 2000; Kamat et al., 2015; Tate et al.,
2003).
Reduced motivation (apathy) in HIV-1 infected individuals can significantly
affect perceived well-being and depression (Tate et al., 2003), medication
adherence (Barclay et al., 2007; Panos et al., 2014), attentional tasks, executive
function and reward-cue processing (Plessis et al., 2015). Apathy is prevalent in
the HIV-1 population with estimates of 30-50% of participants affected (Castellon
et al., 2000; Kamat et al., 2015; Tate et al., 2003). Apathy and self-efficacy were
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found to be the strongest psychosocial predictors of medication adherence in
HIV-1 patients who were taking combination antiretroviral therapies (cART)
(Panos et al., 2014). Yet, despite the prevalence of apathy in the HIV-1+
population, reductions in motivation is understudied. The goal of the present
study was to examine apathy in the HIV-1 population in a pre-clinical animal
model, the HIV-1 Transgenic (Tg) rat.
Motivation, or the lack thereof (apathy) in HIV-1 patients, may be due to
basal ganglia atrophy, which is apparent in HIV-1 seropositive individuals through
brain imaging techniques (Paul et al., 2005). Basal ganglia atrophy is associated
with reduced motivation in the HIV-1 population (McIntosh, Rosselli, Uddin, &
Antoni, 2015). These findings suggest the dopamine system in HIV-1 patients is
altered by the HIV-1 associated neurotoxic proteins. In the majority of pertinent
literature (Castellon et al., 2000; Cole et al., 2007; Kamat, Woods, Marcotte, Ellis,
& Grant, 2012; Kamat et al., 2015; Levy & Dubois, 2006; Paul et al., 2005),
apathy carries a shared definition, and was defined initially by Marin (1991) as: “a
syndrome of primary motivational loss, that is a loss of motivation not attributable
to emotional distress, intellectual impairment, or diminished level of
consciousness” (Marin, 1991).
The HIV-1 Tg rat is one animal model for the study of HIV-1 disease
progression and neurocognitive alterations (Moran, Aksenov, Booze, Webb, &
Mactutus, 2012; Moran, Booze, Webb, & Mactutus, 2013). Of the 9 genes
encoded by the HIV-1 virus, 7 are expressed in the HIV-1 Tg rat. The genetic
alterations which occur in HIV-1 patients, and the aviremic state of patients
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whom are on cART (Peng et al., 2010; Vigorito, Connaghan, & Chang, 2015) can
be replicated by the HIV-1 Tg rat animal model. The pol protein (1 of the 2 nonexpressed proteins) is utilized in transcription and replication of the HIV-1 virus;
therefore an aviremic state is replicated in the HIV-1 Tg rat. The neurotoxic
proteins found within the central nervous system (CNS) continue to be expressed
in the HIV-1Tg rat, similar to what is found in human HIV-1+ individuals (Brew et
al., 2015; Peng et al., 2010; Rappaport & Volsky, 2015) adhering to cART.
The HIV-1 Tg rat was developed through embryonic delivery of a noninfectious provirus, with the gag and pol genes deleted. The transgene was
located on one allele in the initial female founder (hemizygous). The animal was
bred with a wild-type (WT) inbred F344; pups with either the HIV-1 transgene
(HIV-1 Tg) or wild type (Tg-WT) were created from the breeding combination.
The HIV-1 transgene is incorporated into all cells (20-25 copies) of the HIV-1 Tg
rat, causing opaque cataracts (Reid et al., 2001). The viral gene env (envelope
protein), is an essential gene for the HIV-1 provirus to attach to the lipid bilayer of
the host cell (macrophages and CD4+ T cells), is coded by the transgene. The
gp160 precursor is coded by the env protein, and then is cleaved into gp120 and
gp41 (McCune et al., 1988) which collectively allow the virus to bind to the CD4
glycoprotein or chemokine (CCR5 or CXCR4) receptors on the host cell’s surface
(via gp120) and deliver its viral contents (via trimeric gp41) (Chan & Kim, 1998;
Wyatt & Sodroski, 1998). While the HIV-1 associated proteins (env, tat, rev, vif,
vpf, vpu and nef) are produced in the animal model (Peng et al., 2010; Reid et
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al., 2001), the HIV-1 Tg animal model is not suitable to examine the viral
replication or transmission stages (due to the pol and gag deletions).
However, the HIV-1 Tg rat is ideal for examination of neurocognitive
alteration in individuals who adhere to cART. As stated previously, 7/9 of the
HIV-1 viral proteins are expressed by the HIV-1 transgene throughout
development and into adulthood and old age (Abbondanzo & Chang, 2014). The
HIV-1 Tg rat provides a tool for examination of HIV-1 neural alterations through
continued expression of the HIV-1 associated viral proteins. The HIV-1 Tg rat is a
promising model for examination of potential theraputics for HIV-1 cognitive
progressive decline and, as hypothesized, motivational deficiencies. Thus far, the
HIV-1 Tg rat has been used to study neurological deficiencies (Moran et al.,
2013; Moran, Booze, & Mactutus, 2013; Moran, Booze, & Mactutus, 2014; Peng
et al., 2010; Royal, III, Wang, Jones, Tran, & Bryant, 2007; Royal, III et al., 2012;
Vigorito et al., 2015), sensorimotor gating (Moran et al., 2013; Moran et al., 2013;
Moran, Hord, Booze, Harrod, & Mactutus, 2015), attention and inhibition (Moran
et al., 2014), and medium spiny neuron (MSN) dendritic spine alterations
(Roscoe, Jr., Mactutus, & Booze, 2014).
Significant reductions in locomotor activity (June, Tzeng Yang, Bryant,
Jones, & Royal, III, 2009; Midde, Gomez, Harrod, & Zhu, 2011; Moran et al.,
2013) as well as differential rates of habituation to the activity apparatus (Moran
et al., 2013) compared to controls, have been previously reported in the HIV-1 Tg
rat. These findings suggest the motivation for exploration or escape may be
reduced in the HIV-1 Tg rat. The purpose of the present study was to examine
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apathy and reduced motivation in the HIV-1 Tg rat. It was hypothesized the HIV-1
Tg rat would exhibit reduced intrinsic motivation compared to age-matched
controls.
Research in human seropositive individuals has shown the circadian
rhythms of HIV-1 patients is altered, with 50-70% reporting disturbances in sleep
onset (insomnia), daytime sleepiness, and fragmented sleep during standard
sleeping hours. Altered circadian rhythms (reduced amplitudes) has been shown
to be directly caused by the Transactivator of Transcription (Tat) protein (Clark,
III, Sampair, Kofuji, Nath, & Ding, 2005; Duncan et al., 2008; Wang et al., 2014),
and the altered circadian rhythmicity has been found in both human (Wang et al.,
2014) and animal models (Clark, III et al., 2005; Huitron-Resendiz, Marcondes,
Flynn, Lanigan, & Fox, 2007). The goal was to determine if chronic expression of
the Tat protein affects the capacity for entrainment to new or altered light and
dark cycles. It has been previously reported, Tat is capable of altering the
established circadian cycle-induced animal metabolic frequency amplitudes in
models of HIV-1 progression (reduced circadian rhythm amplitude) (Duncan et
al., 2008; Huitron-Resendiz et al., 2007). As alterations in circadian patterns may
affect diurnal/nocturnal running behaviors differentially, circadian influence on the
HIV-1 Tg rat in relation to motivation was examined. Alterations in the circadian
rhythms of the HIV-1 Tg rat would be elucidated by the voluntary wheel running
task and experimental time-of-day manipulations if they were apparent was the
goal of the current study.
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Motivated behaviors in rats, such as area exploration and wheel running,
are dependent upon ventral tegmental area (VTA) dopaminergic activation of the
nucleus accumbens (NAc) medial prefrontal cortex (mPFC) (mesocorticolimbic
dopaminergic pathway) (Basso & Morrell, 2015; Greenwood et al., 2011;
Mogenson, Wu, & Manchanda, 1979; Mogenson & Yang, 1991; Pijnenburg,
Honig, Van der Heyden, & Van Rossum, 1976; Rhodes, Gammie, & Garland, Jr.,
2005; Roberts et al., 2012). Previous research has shown when the
dopaminergic activity of mesocorticolimbic pathway is upregulated (SKF82958,
methylphenidate (Ritalin™), cocaine, GBR 12909) or downregulated (SCH23390,
Bupivacaine, and muscimol) through pharmacotherapies, the motivation for
running is increased or decreased (respectively) in both the acquisition and
habitual phases of wheel running (Basso & Morrell, 2015; Rhodes et al., 2005;
Roberts et al., 2012). Additionally, when animals are forced to abstain from the
running wheels (deprivation), upon running wheel return the animals show a
“rebound effect” (i.e. increase) in their running distances (Basso & Morrell, 2015;
Mueller, Herman, & Eikelboom, 1999; Skinner B.F., 1933). The rebound effect in
wheel running suggests the activity has rewarding properties for the animals,
similar to those found after deprivation of other naturally rewarding stimuli
(Heffner, Hartman, & Seiden, 1980), or pharmacological (drug) rewards
(McSweeney, Murphy, & Kowal, 2005). Voluntary wheel running was a freechoice activity for the animals, therefore it was hypothesized that wheel running
was a task capable of assessing intrinsic motivation in the HIV-1 Tg rat for a
naturally rewarding stimulus.
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Within the mesocorticolimbic pathway, MSNs of the NAc act as inhibitory
(GABAergic) regulators of the dopaminergic efferent projections from the VTA,
and the glutamatergic efferent projections from the mPFC (Purves et al., 2012a;
Purves et al., 2012b). As the MSNs of the NAc are structurally altered in the HIV1 Tg rat (Roscoe, Jr. et al., 2014), it is possible the motivational state of the HIV1 Tg rat is effected due to neural alterations of the NAc. Neuronal synapses and
dendritic spines are subject to increased dendritic loss and aberrant sprouting of
synaptodendritic connections and reduced plasticity in HIV-1 patients; for review
see (Avdoshina, Bachis, & Mocchetti, 2013; Ellis, Langford, & Masliah, 2007).
MSNs of the nucleus accumbens are structurally altered in the HIV-1 Tg rat
according to previous reports (Roscoe, Jr. et al., 2014). The
motivational/rewarding efficacy of naturally rewarding behaviors may be effected
by alterations of the mesocorticolimbic pathway (Purves et al., 2012a). As the
nucleus accumbens is sensitive to and targeted by, HIV-1 neural proteins
resulting in neural alterations, it was paramount to histologically examine these
areas. Specifically, the nucleus accumbens, and the inhibitory MSNs it contains,
are an essential feature of the subcortical circuitry of the reward/motivation
pathway. As voluntary wheel running requires mesocorticolimbic activation,
histological examination of the MSNs of the NAc was conducted. Previously, it
has been reported the HIV-1 Tg rat has altered dendritic spines on the MSNs of
the NAc, with significant alterations in dendritic spine length and volume
measures (Roscoe, Jr. et al., 2014) compared to controls. Consequently,
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motivated behaviors such as voluntary wheel running may be impacted by
alterations in MSN dendritic spine morphology.
In summary, motivation in the HIV-1 Tg rat was tested using locomotor
activity in an activity chamber and a voluntary running wheel. To determine if
there are any motivational differences due to a genotype × diurnal phase
interaction, diurnal influences were compared between the HIV-1 Tg rat and
F344 controls. These manipulations were done to assess the effect of HIV-1 on
circadian rhythmicity of voluntary wheel running in the HIV-1 Tg rat compared to
age-matched controls. Further insight into motivation deficiencies was provided
by examination of the MSNs of the NAc. Altered synaptodendritic connections in
the reward/motivation pathway (mesocorticolimbic) were due to MSN alterations
in dendritic spine parameters, which behaviorally created a reduced motivational
state in the HIV-1 Tg rat. To date, there are no publications on the MSNs of the
NAc immediately following a behavioral task in the HIV-1 Tg rat.
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CHAPTER 2
METHODS
2.1 SUBJECTS
Ovariectomized female Fisher (F344/N; Harlan Laboratories Inc.,
Indianapolis, IN) rats (F344 controls, n=26 and HIV-1 Tg, n=21) arrived at the
facility at postnatal day (PND) 46-60 (1 ½-2 months of age). All animals were
pair-housed throughout the experiments and randomly assigned numbers for
identification and wheel apparatus assignment. Rodent food (2020X Tekland
Global Soy Protein-Free Extruded Rodent Diet (Soy Protein-Free)) and water
were available ad libitum for the entirety of the study. Animals were maintained
according to the National Institutes of Health (NIH) guidelines in AAALACaccredited facilities. The animal facility was maintained at 21° ±2° Celsius, 50% ±
10% humidity and had a 12-hour (h) light/12h dark cycle with the lights on at
0700h (EST). The project protocol was approved by the Institutional Animal Care
and Use Committee (IACUC) of the University of South Carolina, animal
assurance number A3049-01. An overview of the experimental testing sequence
is shown in Table 2.1.

2.2 BODY WEIGHTS:
All animals were handled and weighed 5 days per week from the day they
arrived at the facility (PND 46-60) for the duration of the study to observe animal
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overall health on a digital scale, with weights to the tenth of a gram (Mettler
Toledo, Columbus, OH).

2.3 LOCOMOTOR ACTIVITY
2.3.1 Apparatus
Animals were tested in activity chambers (40cm x 40cm) fitted with a
circular Plexiglas insert to promote animal movement and prevent animals from
stopping in the corners of the apparatus (Hughes & Beveridge, 1986; Hughes,
Lowther, & van, 2011; Moran et al., 2013). Ambulation and animal rearing in the
X and Y axis was recorded via infrared photocells spaced 2.5cm apart (HamiltonKinder Inc., Ponway, CA). Photocell breaks were recorded by Digipro Systems
Software (v.140, AccuScan Instruments). The dependent measures of gross,
fine, and rearing movements were defined by the monitoring software Motor
Monitor (Hamilton-Kinder Inc., Ponway, CA). Locomotor activity was recorded
and grouped in 5-minute bins. Gross movement was classified as clearing of the
anchor beam when a new beam was broken, while fine movements (such as
head movements) were defined by new beam breakage without clearance of the
anchor beam. Photocell pairs were tuned by the manufacturer to control for extra
perspex width due to the presence of the circular Plexiglas insert (~40cm in
diameter).

2.3.2 Procedure (Phase I): Locomotor activity
Activity testing was performed once per week for seven consecutive
weeks. Animals were placed in the center of the activity chamber and recording
10

initiated. Animals were tested from 1200h to 1600h under low-light conditions (10
Lux). White noise of 70db was played in the testing room for the duration of the
activity measure (60 minutes). Animal testing was block-randomized through
Latin Square design for testing session and chamber assignment to control for
time of day and box proximity to the light/sound source.

2.4 RUNNING WHEELS
2.4.1 Apparatus
The running wheel apparatus was a polypropylene rectangular chamber
(45.5cm long, 24cm wide and 20.5cm deep) with a 34cm diameter running wheel
attached to the chamber lid at the midpoint. Magnetic sensors on the lid and
wheel recorded revolutions by the recording software. All data was recorded by
Vital View 4.0 (Mini Mitter Inc., Bend, OR) software which records wheel
revolutions. The data was collected into 1-minute cumulative bins for wheel
revolutions.

2.4.2 Diurnal Procedure (Phase II): Wheel Running
The animals were tested in voluntary wheel running in the diurnal phase of
their light/dark cycle following open-field activity testing. Testing was performed
from 12:00 to 17:00 each day for ~66 minutes, 7 days per week. Testing was
continued until stability was reached in overall group running distance for 3
consecutive weeks (not significantly different). Animals were assigned to their
running wheel chamber through Latin-Square design to ensure an equal chance
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to be tested in any chamber or running group (time of day). Diurnal running
sessions were performed in low-light conditions (10 lux). Following the wheelrunning session, animals were returned to their home cage until the next session
the subsequent day.

2.4.3 Nocturnal Procedure (Phase III): Wheel Running
Once diurnal stability in both groups was established, animals were then
tested during the nocturnal phase of their light/dark cycle, with testing initiated at
19:00 and continuing until approximately 24:00, following the same procedure as
diurnal running sessions. The animals were placed in the same designated wheel
chamber as previously assigned and tested in the dark (<10 lux). Animals were
run 7 days/week until running distances for both groups stabilized for 3
consecutive weeks.

2.4.4 Deprivation/Response trials (Phase IV): Wheel Running
Following 3 weeks of stabilized asymptotic nocturnal running performance,
the running wheels were locked for either 1, 2, or 3 days to measure group
responsiveness to varying locked wheel durations, and determine if the response
was similar in both groups. The sequence of Phase IV is shown in Table 2.2.
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2.4.5 Diurnal Return: Wheel Running
To determine if the increased running in the nocturnal sessions was a
consequence of learning or conditioning, animals were returned to the diurnal
schedule for one week following Phase IV (Deprivation/Response phase). It was
hypothesized a return to distances previously established during diurnal
recording (Phase II) would support the notion that the differences found between
diurnal/nocturnal running sessions (Phase II & III) were a product of a wellentrained circadian cycle. Running distances between diurnal stabilized levels
(Phase II) and nocturnal stabilized levels (Phase III) would suggest a learning or
conditioning phenomenon had taken place.

2.4.6 Peak running speed: Wheel Running
Individual peak running speed was determined as: peak speed= 95th
percentile * Wheel circumference (106.76cm) (Mahoney et al., 2013; Ottenweller
et al., 1998) during both diurnal and nocturnal running sessions (analyzed
separately). Peak running speed was determined by the 95th percentile of wheel
revolutions during any 1-minute bin. Wheel running data (Phase II & III) was
analyzed to determine individual and group average peak running speed.
Individual peak speed data was analyzed for genotype differences.

2.4.7 Motivation for running initiation latency: Wheel Running
The latency for the groups to initiate their first revolution during diurnal and
nocturnal running sessions (Phase II & III) was examined. Latency for initiation
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was determined through individual data from each phase. Initiation latency was
defined as: initiation latency = group average of the number of minutes from the
start of the session until the first revolution. Diurnal and nocturnal initiation
latency was analyzed separately.

2.4.8 Running Bout length and frequency: Wheel Running
Running bouts were determined by: number of minutes in which at least 1
wheel revolution occurred in sequence until no revolutions occurred (quiescent)
(Eikelboom & Mills, 1988). Running bouts were analyzed for bout length and total
number of bouts similar to previous studies (Eikelboom & Mills, 1988).

2.5 HISTOLOGY
2.5.1 Euthanasia Procedure
At the end of the study, all animals were tested one last time. At the end of
~66 minutes, the animals were removed from the wheel apparatus and
immediately deeply anesthetized with sevoflurane and then transcardially
perfused with ~100ml of 100mM PBS followed directly by ~150ml of chilled 4%
paraformaldehyde buffered in PBS (Sigma-Aldrich, St. Louis, MO). Brains were
removed and post-fixed in 4% chilled paraformaldehyde for 10 minutes, notched
for orientation, then sectioned in 200µm thick coronal slices using the rat brain
matrix (ASI Instruments, Warren, MI). Sequential slices were placed in a 24-well
plate (Corning, Tewksbury, MA) with 1ml PBS until processed.
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2.5.2 Preparing the DiOlistic cartridges
Tungsten beads (175mg, Bio-Rad, Hercules, CA) were dissolved in
~0.3ml of 99.5% methylene chloride (Sigma-Aldrich, St. Louis, MO). Crystallized
DiI (7mg, Life Technologies, Grand Island, NY) was dissolved in ~0.3ml
methylene chloride. All of the bead solution was applied to a glass slide and
allowed to air dry completely. The DiI solution was added to the affixed tungsten
beads on the glass slide and mixed slowly with the pipette tip until completely
dried. A razor blade was used to scrape the dye/bead mixture into two (2) 1.5ml
Eppendorf™ (Eppendorf North America, Hauppauge, NY) tubes with 1.5 ml of
ddH2O water. These two tubes were probe sonicated with a Branson Sonifier
150 (Branson Ultrasonics; Danbury, CT) for a minimum of 10 minutes to ensure
complete breakup of the beads which had adhered together by the DiI solution.
The two tubes were then combined into a 15ml (BD Falcon, San Jose, California)
and sonicated further until used later.

2.5.3 Preparation of Tefzel Tubing
First, ~70cm of new Tefzel tubing (IDEX Health Sciences, Oak Harbor,
WA) was cut. Polyvinylpyrrolidone (PVP) (100 mg Sigma-Aldrich, St. Louis, MO)
was dissolved into 10ml of ddH2O, vortexed, and drawn into the Tefzel tubing
and allowed to sit for a minimum of 10 minutes. When ready, the PVP was
removed from the tube and the DiOlistic mixture was drawn into the tube
between periodic vortexes to maintain homogenization. The filled tubing was
placed in the tubing prep station (Bio-Rad, Hercules, CA) and rotated for 5
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minutes. Rotation was stopped momentarily while the remaining water was
slowly drawn from the tubing, and rotation resumed for another 30 minutes.
Nitrogen gas was added to ensure drying for another 30 minutes at a flow rate of
0.4 L/m. Once dry, the tubing was cut into 13mm segments and stored in a dark
condition.

2.5.4 DiOlistic Labeling using the Helios Gene Gun
For labeling of the MSNs in the NAc (from Bregma 3.24mm-.48mm, plates
10-29 (Paxinos & Watson, 2007), slices were DiOlistically labeled using the
Helios Gene Gun (Bio-Rad, Hercules, CA) following the initially reported
procedure (Roscoe, Jr. et al., 2014; Seabold, Daunais, Rau, Grant, & Alvarez,
2010). Bullets were ballistically delivered once at ~90 PSI to the coronal slices,
through a 3μm pore filter paper with the sample ~2.5cm away from the gun
barrel, slices were washed 3x to ensure excess DiI coated tungsten bullets were
removed from the wells. These slices were stored in PBS at 4° C in the dark
overnight to allow dye diffusion before mounting.

2.5.5 Mounting of NAc slices and slide preparation
Following DiOlistic labeling, Slices 3, 4, & 5 from the rat brain matrix
(approximately Bregma 2.28-1.00, (Paxinos & Watson, 2007); plates 14-25) were
used for imaging of the NAc MSNs. Three slices per animal were placed on 25 x
75 x 1mm Superfrost Plus slides (VWR, Radnor, PA), completely covered using
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ProLong Gold antifade reagent (Life Technologies, Grand Island, NY) and
coverslipped with 22x50mm VWR micro cover glass (VWR, Radnor, PA).

2.5.6 Imaging and Spine Measurement
Slices were imaged with a Nikon TE-2000E confocal microscope, using
Nikon’s EZ-C1 computing software (v. 3.81b) to create Z-stacked images of the
DiOlistically labeled neurons in the NAc and analyzed by dendritic spine analysis
software. Z-stacks of the MSNs of the NAc were created to build 3-dimensional
reconstructions of the neurons to measure the dendritic spines of the MSNs. The
anterior commissure was used as a reference point to find the NAc area in each
slice. These 3-dimensional images were analyzed using Neurolucida (v. 10.52)
AutoNeuron and Autospine (MicroBrightField, Williston, VT) modules to measure
the dendritic spine length and head diameter.

2.5.7 Dendritic Spine Parameters
Dendritic spine measurements of the MSN’s of the NAc was quantified by
Autospine software which measured dendritic spine in length and head diameter.
Spine length was quantified for all spines of .01-4μm in length. Spines greater
than 5μm in length were determined as filopodia and were excluded from the
analysis of the data. Spine head diameter of .3-1.2μm were included in the
analysis as previously reported (Roscoe, Jr. et al., 2014).
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2.6 STATISTICAL ANALYSIS
Data analyses were performed using SPSS version 22 (IBM Corp.,
Somers, NY) and figures were produced with GraphPad Prism version 5.02
(GraphPad Software, Inc., La Jolla, CA). Animal weights were analyzed with a 2way mixed model ANOVA with genotype (F344 control vs. HIV-1 Tg) as the
between subjects factor, and animal age (PND) as the within subjects factor for
analysis. All statistical adjustments for violations of the sphericity assumptions
used the most conservative method, Greenhouse-Geisser degrees of freedom
correction factor (Greenhouse & Geisser, 1959) and were reported as: pGG.
Mauchly's test of sphericity was used to determine violations of the sphericity
assumption. An α of p≤.05 was considered statistically significant.
For analysis of Phase I open-field activity measures, a 3-way mixed model
ANOVA with genotype (F344 control vs. HIV-1 Tg) as the between-subjects
factor with week (7 weekly repetitions) and bin (12, 5-minute bins) as withinsubjects factors was used. Animal gross movements, fine movements and
rearing were analyzed. It was hypothesized that significant differences between
groups in locomotor activity, similar to previous reports (June et al., 2009; Midde
et al., 2011; Moran et al., 2013) would be found in the current study of the HIV-1
Tg rat.
To determine if there was a significant difference between the two
genotype groups in diurnal running; Phase II and Phase III running distances
were compared through a 2-way mixed model ANOVA, with genotype (F344
control vs. HIV-1 Tg) as the between-subjects factor and Day serving as the
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within-subjects factor. Running bout length and number of running bouts was
analyzed with a 2-way mixed model ANOVA, with identical variables in the
analysis. Diurnal and nocturnal running were analyzed separately as it was
hypothesized there would be an effect of testing time-of-day manipulations.
Phase IV (Deprivation/Response) running distances were analyzed with a
2-way mixed model ANOVA with genotype (F344 control vs. HIV-1 Tg) as the
between subjects factor and locking duration (1, 2, or 3 nights locked) as the
within subjects factor of the analysis. Running bout frequency was analyzed with
Chi-Square Independence tests to determine differences between genotype
groups in the frequency of the number of running bouts between stabilized
running levels (last week of nocturnal running sessions) and number of running
bouts in response to the deprivation of the running wheel.
Diurnal Return analysis was analyzed with a 3-way mixed model ANOVA
with genotype as the between subjects factor and week set (Last week vs.
Diurnal Return) and Day as within subjects factors in the analysis. Stabilized and
Diurnal Return running bout length and frequency were analyzed with a 3-way
mixed model ANOVA and analyzed with identical variables. Peak running speed
for the groups was analyzed with one-way ANOVA to assess the effect of the
HIV-1 genotype on maximum speed attained. For analysis of running initiation
latency, a one-way ANOVA was used to compare group latency to initiate
running behaviors. Running bout data were analyzed with 2-way mixed model
ANOVA, with genotype as the between subjects factor in the analysis, and Day
as the within subjects factor. In addition, the frequency of the number of running
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bouts was analyzed with Chi-Square Independence tests, to examine population
changes in the number of running bouts frequency between the two groups.
Diurnal and Nocturnal sessions were analyzed separately.
Spine measurements of length and head diameter were analyzed as a
population; frequencies of dendritic spine measurements were analyzed through
Chi-Square Independence tests to determine any effect of the HIV-1 transgene
on dendritic spine length and head diameter (analyzed independently) as a
population.
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Table 2.1: Experimental Design table
Phase of
Fixed Effects
Phase Breakdown
Study
Fixed effect:
Weekly Open-Field
Genotype
Phase I
activity measures
2 Levels (Control &
(Total 7 weeks)
HIV-1 Tg)
Fixed effects:
Diurnal voluntary
Genotype,
wheel running until
2 Levels (Control &
group asymptotic
HIV-1 Tg)
Phase II
performance for 3
Diurnal Phase
consecutive weeks
2 Levels (Diurnal &
Total of 5 weeks (35
Nocturnal)
days)

Phase III

Nocturnal voluntary
wheel running until
group asymptotic
performance for 3
consecutive weeks
Total of 8 weeks (56
days)

Phase IV

Nocturnal
extinction/reinstatem
ent trials
Total of 1.5 weeks
(10 days)

Diurnal
Return

Diurnal voluntary
wheel running
following nocturnal
and extinction
phases
Total of 1 week, (7
days)

Fixed Effects:
Genotype,
2 Levels (Control &
HIV-1 Tg)
Nocturnal Phase
2 Levels (Diurnal &
Nocturnal)

Fixed Effects:
Genotype,
2 Levels (Control &
HIV-1 Tg)
Length of extinction,
3 levels (1, 2, or 3
days of extinction)

Fixed Effects:
Genotype,
2 Levels (Control &
HIV-1 Tg)

Random effects
Random Effect:
Within-subject
variability over 7
trials
Random Effect:
Within subject total
running distance
over course of
diurnal running,
Within subject
latency to initiate
running
Random Effect:
Within subject
variability in total
running distance
over course of
nocturnal running,
Within subject
latency to initiate
running
Random Effect:
Within subject
variability in total
running distance
over 3 days of
reinstatement,
Within subject
latency to initiate
running
Random Effect:
Within subject
variability in total
running distance
over 3 days of
reinstatement,
Within subject
latency to initiate
running

Table 2.1: Experimental Design table of each experimental phase of the study.
Each phase of the study was run sequentially following the termination of the
previous phase.
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Table 2.2: Phase IV sequence

Day:
1
Wheel X
Status:

2
3
Response X
recording

4
X

5
6
Response X
recording

7
X

8
X

9
Response
recording

Table 2.2: Breakdown of sequential order of Phase IV deprivation/response trials.
Each response trial followed a deprivation series, of which the length of the
wheel locking was manipulated.
*Note: X=Running Wheel locked during nocturnal session.
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CHAPTER 3
RESULTS
3.1 BODY WEIGHTS
Animal body weight analysis of the 45 animals which provided weight data
for all days of the current study, showed the HIV-1 Tg animals weighed
significantly less than their F344 control counterparts across the 192 days of
weights analyzed F (1, 43) = 26.899, pGG ≤.05, (Figure 3.1). Animal body weights
showed a significant effect of Day (i.e. animal age) F (191, 8213) = 959.311, pGG
≤0.05, with a non-significant interaction between Day*Genotype F (191, 8213)
=1.512, pGG >0.05.

3.2 LOCOMOTOR ACTIVITY
3.2.1 Gross Movement:
A significant main effect of Day F (6,270) =6.91, pGG ≤.05, and Bin F (11,
495) = 619.19, pGG ≤.05, and Genotype F (1, 45) =33.66, pGG ≤.05 in gross
locomotor activity was found (Figure 3.2). Animal Genotype x Bin interactions
were significantly different between groups: Bin*Genotype: F (11, 495) = 7.72,
pGG ≤.05; whereas Genotype*Day was not significant: F (6, 270) =1.191, pGG
>.05. The 3-way interaction of Bin x Day x Genotype was significant F (66, 2970)
= 1.819, pGG ≤.05.
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3.2.2 Fine Movement:
Results showed a main effect of Day F(6, 270) =27.04, p≤.05; and Bin
F(11,495) =693.321, pGG ≤.05, and Genotype F(1, 45) =19.50, p≤.05, (Figure 3.3)
in animal fine movements in the activity chambers. A significant 2-way interaction
was found in the Bin*Genotype interaction F(11, 495) =8.44, pGG ≤.05; while the
Day*Genotype interaction was not significant F(6, 270) =.268, p>.05. The 3-way
interaction of Day*Bin*Genotype was not significant for fine movements, F (66,
2970) =1.12, pGG >.05.

3.2.3 Rearing:
Results showed a main effect of Day F(6, 270) =46.99, p≤.05; and Bin F
(11,495) =543.00, pGG ≤.05, as well as Genotype F(1, 45) =19.50, p≤.05. A
significant 2-way interaction was found in the Bin*Genotype interaction F(11,
495) =9.09, pGG ≤.05; and the Day*Genotype interaction was significant F(6, 270)
=.2.63, p>.05 (Figure 3.4). The 3-way interaction of Day*Bin*Genotype was not
significant for animal rearing, F(66, 2970) =1.06, pGG >.05.

3.3 WHEEL RUNNING
3.3.1Diurnal Running
Diurnal running sessions showed a significant difference between days in
diurnal running sessions across the 35 consecutive days of diurnal running (5
weeks, 7 days/week) F(34, 1530)=16.41, pGG ≤0.05 (Figure 3.5). However, there
was no significant difference between genotype groups in diurnal running
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sessions F(1, 45) =0.015, pGG >0.05; nor a significant interaction effect between
diurnal running sessions* genotype F(34, 1530) =.999, pGG >0.05.
The diurnal running bout analysis showed a significant effect of running
Day F(34, 1530) = 2.925, pGG ≤ .05,no significant difference between groups F(1,
45) = 1.428, pGG>.05, and a non-significant interaction of Genotype*Day F(34,
1530) =.599, pGG>.05. Additionally, a significant effect of Day F(34, 1530) =
5.431, pGG≤.05, a non-significant main effect of Genotype F(1, 45) = pGG >.05,
and a non-significant interaction of Day*Genotype F(34, 1530) = pGG >.05 were
found in the number of running bouts.

3.3.2 Nocturnal Running
A significant difference between days F(55, 2420) =5.123, pGG ≤0.05; a
non-significant difference between genotypic groups F(1, 44) =.031, pGG >.05 in
nocturnal running sessions was found. There was a significant interaction
between nocturnal running sessions * genotype F(55, 2420) =1.99, pGG ≤0.05
(Figure 3.5).
Analysis of nocturnal running bout length showed a non-significant main
effect of Genotype: F (1, 45) = 1.451, p>.05; and Day: F (48, 2160) = 1.566, pGG
>.05, the interaction was also non-significant Day*Genotype: F (48, 2160) pGG
>.05. However, the analysis of the number of running bouts during the nocturnal
sessions showed a significant effect of Genotype F (1, 45) = 5.036, p≤ .05, a
significant effect of Day F (48, 2160) = 3.590, pGG ≤ .05, and a non-significant
interaction of Day*Genotype F (48, 2160) = .645, pGG >.05 (Figure 3.6).
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The number of running bouts of the first 3 weeks of the nocturnal sessions
(Weeks 6, 7, & 8) and the subsequent 3 weeks (Weeks 10, 11, & 12) was
examined. The analysis showed a significant main effect of genotype F(1, 44) =
13.933, p≤.05; a significant effect of "Day" for each set of weeks F(20, 880) =
4.371, pGG ≤.05; a non-significant effect of the "week set" (Weeks 6,7 8 vs.
Weeks 10,11 ,12): F(1, 44) = 3.742, p=.06; and the Day*Week set interaction
was significant F(20, 880) = 3.635, pGG ≤.05. No other interaction between
Genotype or Week set proved significant.

3.3.3 Maximal Speed
Maximal running speed for the groups was determined (F344 Controls
mean=31.04, SEM=2.732; HIV-1 Tg mean=32.52, SEM=3.129). 1-way ANOVA
analysis showed the groups were not significantly different in their maximal
running speeds: F (1, 45) = .129, p>.05.

3.3.4 Latency to Initiate Running
Latency to initiate running behavior was examined. Latency to initiate
running was determined by quantifying the time taken (in minutes) to record the
first revolution of the running wheel in each nocturnal session. The 1-way
ANOVA showed no significant difference in latency to initiate running based on
Genotype: F344 Control (mean=1.745, SEM=.447); HIV-1 Tg (mean=1.055,
SEM=.447) F (1, 45) =1.171, p>.05.
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3.3.5 Deprivation/Response
Deprivation/response data was analyzed to determine the effect of the
wheel locking compared to stabilized running distances on the final week of
nocturnal running. A 2-way mixed model ANOVA was used for analysis, and
showed wheel locking significantly increased the animal's running distance
compared to their nocturnal running distances of the previous week: F(3, 132) =
3.717, p≤.05, (Table 3.1). Between groups variances were analyzed through
mixed model ANOVA, and showed the significant results on wheel locking
duration were not due to genotype differences F(1, 44) = .750, p> .05.The
interaction of Response*Genotype was also not significant: F(3,132) = .379,
p>.05. An increase in animal running distances following locking of the wheels
suggests the running activity was rewarding for the animals, similar to previously
published studies which deprived animals from rewards (Amsel & Roussel, 1952;
Heyse, Brenes, & Schwarting, 2015; Kagan & Berkun, 1954).
Additionally, the number of running bouts during stabilized nocturnal
running weeks compared to the number of Deprivation/Response running bouts
(Figure 3.7) through Chi-Square Independence tests were examined. The
analysis showed the relationship between genotype * stabilized week was
significant LX2(15, N=329) = 40.330, p≤.05, and the relationship between
genotype * Deprivation/Response was significant LX2(14, N=141) = 28.890,
p≤.05. The relationship of stabilized week * Deprivation/Response was not
significant LX2(196, N=141) = 155.238, p>.05. The results suggest both groups
significantly increased their running distances and number of running bouts in

27

response to the locking of the running wheels, suggesting equal rewarding
efficacy in both groups.

3.3.6 Diurnal Return
A significant difference between the previous final week of diurnal running
distances and the return to diurnal running distances (Figure 3.5, Week 16),
LastvsReturn: F(1, 45)=.126, p>.05 was found, however, a non-significant main
effect of Genotype F(1,45)=.043, p>.05, and a non-significant interaction of
LastvsReturn*Genotype, F(1, 45)=.009, p>.05 was shown. The 3-way interaction
of LastvsReturn*Day*Genotype failed to reach significance: F(6, 270) =.970,
p>.05. The only significant results of the analysis were the effect of Day F(6, 270)
=13.707, p≤.05; and the interaction of LastvsReturn*Day: F(6, 270) =9.492,
p≤.05. The absence of significant differences between the Phase II and the
Diurnal Return running distances showed the increases found during the
diurnal/nocturnal cycles were not indicative of a conditioning phenomenon, and
are a product of circadian entrainment.

3.4 DENDRITIC SPINE ANALYSIS
A Chi-Square test of independence was performed to analyze the
relationship between genotype and dendritic spine measures (See Figures 3.8
and 3.9 for sample of MSN images). The analysis showed Length: Χ2(49,
N=177893) = 181.058, p≤.05 (Figure 3.10), and spine head diameter: X2(90,
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N=127681) = 907.530, p≤.05 (Figure 3.11); were significantly different as a
population between genotypic groups.
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Table 3.1: Deprivation/Response Table of results
Deprivation/
Response
Results

Control % HIV-1 Tg %
Increase
Increase

Number of rats
increasing/decreasing running
distance compared to previous
session
Response I
11.2%
7.1%
F344 Controls: 16/9
HIV-1 Tg: 13/8
Response II 14.2%
18.2%
F344 Controls: 15/9
HIV-1 Tg: 17/3/1nc
Response III 12.0%
16.0%
F344 Control: 11/13/
1nc
HIV-1 Tg: 9/12
Table 3.1: Results of the Deprivation Response series of tests. Notice the
deprivation/response was able to motivate all animals to significantly increase
their running distances compared to stabilized running sessions, regardless of
group membership. Most notable is the number of HIV-1 Tg animals which
increased their running distances during the Response following 2 nights of
locked wheels, with ~85% increasing their running distances. Additionally, both
groups increased their running distances compared to stabilized levels in all
levels of deprivation (1-day, 2-day, and 3-day), suggesting the rewarding efficacy
of the running wheel is not altered in the HIV-1 Tg animals.
Note: nc = No Change in running distance compared to previous session
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Figure 3.1: Animal body weight means of each group by animal age (Postnatal
Day: PND). 95% CIs are plotted. Figure shows the HIV-1 Tg animals grow at the
same rate as the F344 controls, but weigh significantly less than their agematched F344 counterparts. The finding replicates the previously reported
differences in body weights in the HIV-1 Tg rat.
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Figure 3.2: Cumulative group mean gross locomotor activity as measured by
photocell breaks collapsed across the 7 weeks of locomotor assessment in the
activity chambers with 95% CIs. The HIV-1 Tg group showed a significant
alteration in their gross locomotor activity habituation over time following similar
initial locomotor activity. Cumulative representation of the data shows a reduced,
stable trajectory in the HIV-1 Tg rat compared to F344 control's trajectory.
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Cumulative Fine Movements
Mean  95% CI
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Figure 3.3: Fine locomotor activity cumulative means with 95% CIs for each
group, collapsed across the 7 weeks of testing. The graph shows in fine motor
activity (head movements, grooming, etc.) the HIV-1 Tg animals show less fine
motor activity similar to the results of gross locomotor activity (Figure 3.2) and
animal rearing activity (Figure 3.4). Cumulative representation of the data shows
a reduced, stable trajectory in the HIV-1 Tg rat compared to F344 controls.
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Cumulative Rearing Movements
Mean  95% CI
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Figure 3.4: Animal rearing (Y-coordinates) cumulative means with 95% CIs,
collapsed across the 7 weeks of testing. The HIV-1 Tg animals show less rearing
over time compared to the F344 controls. Cumulative representation of the data
shows a reduced, stable trajectory in the HIV-1 Tg rat compared to F344
controls.
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Figure 3.5: Diurnal and Nocturnal mean running distances by group with 95% CIs
(Weeks 1-5, and 6-15 respectively). Week 16 (Diurnal Return) was added for
clarity. As can be seen, the HIV-1 animals showed an earlier plateau in the
overall running distance around week 8, meanwhile the F344 controls continued
to escalate until reaching their plateau around week 11 where they stabilized for
3 consecutive weeks. No discernible differences were found in diurnal sessions
(Weeks 1-5 & 16).
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Figure 3.6: Representation of the number of Nocturnal running bouts. The figure
shows the reduction in the number of nocturnal running bouts as a population in
the HIV-1 Tg animals compared to controls. As a population, the HIV-1 Tg
animals show a significant reduction in the number of running bouts per nocturnal
session (F (1, 45) = 5.036, p≤ .05) compared to controls.
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Figure 3.7: Representation of the number of Nocturnal running bouts, in both the
stabilized week of nocturnal running sessions and the animal's response to wheel
deprivation. The figure shows the reduction in the number of nocturnal running
bouts as a population in the HIV-1 Tg animals compared to controls; and the
finding was repeated during the response phase following wheel deprivation. As
a population, the HIV-1 Tg animals show a significant reduction in the number of
running bouts per nocturnal session in their stabilized weeks: LX2(15, N=329) =
40.330, p≤.05, which carried over to the Response phase of the study: LX2(14,
N=141) = 28.890, p≤.05.
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Figure 3.8: Sample images from F344 control (animal #39). (A) 20x image of
MSN, (B)60x image of same MSN, (C)zoomed 60x image of MSN.
*Note: Dashed boxes are the area examined in the subsequent picture.
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A
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Figure 3.9: Sample images from HIV-1 Tg animals (animal #40). (A)20x image of
MSN, (B)60x image of the same MSN, (C)=zoomed 60x image of MSN.
*Note: Dashed boxes are the area examined in the subsequent picture
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Figure 3.10: Figure of NAc MSN dendritic spine length frequencies. The HIV-1 Tg
rats as a population showed significantly shorter NAc MSN dendritic spines:
Χ2(49, N=177893) = 181.058, p≤.05).

40

Relative Frequency (%)

25

20

F344 Control
HIV-1 Tg

15

10

5

0
0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.1 1.2 1.3

Head Diameter (m)
Figure 3.11: Figure of NAc MSN dendritic spine head diameter frequencies. The
HIV-1 Tg rats as a population showed significantly wider NAc MSN dendritic
spines: X2(90, N=127681) = 907.530, p≤.05.
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CHAPTER 4
DISCUSSION
The motivation of the HIV-1 Tg rat, as well as circadian influences on
voluntary wheel running were examined by the current study. Additionally,
examination of the dendritic spines of the MSNs found in the NAc were
compared. The resulting measurements were compared between the two groups
as a population. Motivational differences in the HIV-1 Tg rat during the nocturnal
phase of the voluntary running activity compared to F344 controls were found.
The motivational differences in the HIV-1 Tg rat were observed and
operationalized through reduced running distances and a reduction in the
number of running bouts. These results were dependent upon circadian
influences, as no differences were found during diurnal testing sessions.
Furthermore, a potential mechanism for the reduction in motivation in the HIV-1
Tg rat, through MSN dendritic spine alterations was shown.
A motivational deficit in the HIV-1 Tg rat for naturally-rewarding voluntary
wheel running compared to age matched controls was established by the current
study. HIV-1 individuals are subject to feelings of apathy, presumable caused by
basal ganglia atrophy (McIntosh et al., 2015; Paul et al., 2005), and neural
alterations from HIV-1 viral proteins. Behaviorally, an increase was shown in the
HIV-1 Tg rat’s nocturnal running distances during their peak activity hours
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(Goff & Finger, 1966; Peng, Jiang, & Hsu, 1980; Shirley M., 1928b). An earlier
plateau in running distances in the HIV-1 Tg group was shown by the results,
suggesting a maximal level of rewarding efficacy was reached earlier in the HIV1 Tg rat. In the present study, it may be argued the reduction in dendritic spine
length and increased head diameter to be potential mechanisms for the reduced
running distances and number of running bouts in the HIV-1 Tg animals.
Additionally, perhaps the reductions in running distances and running bouts were
due to dopamine transporter (DAT) dysregulation (McIntosh, Sexton, Pattison,
Childers, & Hemby, 2015; Midde, Gomez, & Zhu, 2012), thereby affecting the
motivational for a naturally rewarding stimuli. The animals did not show
differential maximal speed, nor an increased latency to initiate their first running
revolution, or an alteration in the rewarding properties of the running wheel was
shown by the running wheel data. Instead, a reduced “desire” or motivation to
perform a naturally rewarding activity consistently, operationalized through
reduced running distances and reduced number of running bouts in the HIV-1 Tg
rats compared to controls was found.
As rats are most active during nocturnal hours (Goff & Finger, 1966; Peng
et al., 1980; Shirley M., 1928b), the reduction in motivation indicated by the
decreased running distances and running bouts was found strictly during the
animal’s most active hours, and not impaired during diurnal sessions compared
to controls. It was also demonstrated with the Diurnal Return data, that the
differences in diurnal and nocturnal running distances were not a product of
conditioning, but rather, an example of entrainment to a natural light/dark cycle.
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The well-entrained circadian cycle suggests the HIV-1 Tg rat does not exhibit
circadian alterations in a motivated behavior and was capable of adjusting to
experimental time-of-day manipulations equal to controls. No deficits in the
rewarding nature of the running activity was shown by the deprivation/response
tests (Mueller et al., 1999) in this sample, but rather a deficiency in the long-term
maintenance and/or escalation of a naturally rewarding activity compared to agematched controls during nocturnal sessions. Nearly equal population shifts in the
number of running bouts per session suggests the motivation for reward following
deprivation is reasonably intact in the HIV-1 Tg rat, which was shown by the
animals in this sample. However, it should be noted an altered running bout shift
was shown by the increases in the bout number between the groups, i.e. the
increase in number of running bouts was greater in the more active controls (top
50%) compared to the more active HIV-1 Tg animals (top 50%).
One of the most striking and informative findings in the study was the
results of the Diurnal Return phase of the experiment. It was initially
hypothesized that returning the animals to the diurnal schedule would result in
the animals running a distance somewhere between their previously established
diurnal running and their stabilized nocturnal running distances as a product of
conditioning. However, the animals returned to the previously stabilized diurnal
distances. Thereby suggesting the differences seen in the transition from diurnal
to nocturnal running were completely entrained to the animal's circadian cycles
and were robust to withstand prolonged manipulations in testing time-of-day.
Circadian activity entrainment is incredibly robust and difficult to dramatically
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uncouple from the natural light/dark schedule beyond a few hours with light/dark
schedule manipulations (Goff & Finger, 1966). In the present study, time-of-day
manipulations were resisted by the HIV-1 Tg animals, which followed their
circadian schedule of activity equally as well as controls. The Diurnal Return
findings are in agreement with the work of Duncan et al. (2008) which found
normal circadian cycles (albeit reduced circadian amplitudes) in mice with neural
Tat expression via doxycycline promoters, suggesting the HIV-1 Tat protein is not
the mechanism of circadian alterations found in HIV-1 seropositive patients.
The possibility the results were due to a latency to initiate running bouts
was assessed. Motor behavior initiation is a hallmark of Parkinson’s disease,
which is a product of dopaminergic basal ganglia alterations (Contreras-Vidal &
Stelmach, 1995). The effects of the dopamine-targeting HIV-1 transgene causing
motor initiation disabilities (Graybiel, 1990; Growdon, Kieburtz, McDermott,
Panisset, & Friedman, 1998) in the HIV-1 Tg animals and thereby reducing their
overall running distances was examined. Motor initiation deficits were not
apparent, as suggested by the latency results, as the groups showed no
significant difference in their initiation of their first running bout in nocturnal
sessions. Animal nocturnal running bout length and frequency were also
examined. A significant reduction in the number of running bouts in the HIV-1 Tg
animals was found, however, no statistically significant differences were found in
running bout length. This finding was attributed as a manifestation of reduced
motivation for the naturally rewarding running behavior.
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The finding of reduced running distances in the HIV-1 Tg animals is in
opposition to that previously reported (Chang & Vigorito, 2006), which found the
HIV-1 Tg rat ran greater distances than weight-matched F344 controls. However,
the Chang and Vigorito (2006) study differed in total animals used (10 vs. 47),
animal sex (males vs. ovariectomized females), running session length
(30minutes vs. 60 minutes), the number of daily diurnal running repetitions (15
vs.35), time-of-day (diurnal vs. diurnal & nocturnal) and weight-matched vs. agematched animals. Differential running distances based upon animal age (Peng et
al., 1980) were shown in animals of different ages. As such, compared to weightmatched groups, superior assessment of motivation for wheel running is provided
by age-matched groups.
The HIV-1 Tg animals displayed structural alterations of their MSNs in the
NAc as shown by the dendritic spine data. A potential mechanism of reduced
motivation in the HIV-1 Tg rat was provided by the finding of significantly reduced
dendritic spine length and increased spine head diameter. As activation of the
mesocorticolimbic pathway is essential for motivated, naturally rewarding
behaviors (Basso & Morrell, 2015; Greenwood et al., 2011; Mogenson et al.,
1979; Mogenson & Yang, 1991; Pijnenburg et al., 1976; Rhodes et al., 2005;
Roberts et al., 2012), motivational alterations may be produced by alterations of
the MSNs of the mesocorticolimbic pathway. Collectively, the behavioral analysis
coupled with the histological data suggests it may be the case.
Alterations of the dendritic spines as a population compared to controls
suggests synaptodendric injury or alterations in the structural proteins of dendritic
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spines are occurring in the HIV-1 Tg rat. Altered NAc MSN dendritic spines
potentially led to the reductions in motivation found in the data of the HIV-1 Tg
rat, which was assessed through reduced wheel running distances and
reductions in the number of running bouts. A potential mechanism of the increase
in immature dendritic spines (shorter and stubbier) in the HIV-1 Tg rats may be
alterations of the GTPases related to the actin assembly of dendritic spines.
Multiple mechanisms are responsible for dendritic alteration in dendritic plasticity
spine growth and morphological changes, one of which is the small GTPases:
Ras-related C3 botulinum toxin substrate 1 (Rac1) and Ras homolog gene
family, member A (RhoA) (Lai & Ip, 2013). Rac1 is responsible for spine growth
via activation of the PAK1 and LIMK1 while RhoA regulates and inhibits spine
formation and stabilization. Coincidentally, the Tat protein has been shown to
activate the RhoA signaling pathway in vitro (Krogh, Lyddon, & Thayer, 2015).
Upregulation of the RhoA pathway in vivo from chronic Tat exposure would
theoretically keep spines in a state of immaturity resulting in reduced synaptic
efficiency. Further insight into the neurobiological alterations in the HIV-1 Tg rat
was provided by the histological examination of the MSNs of the HIV-1 Tg rats.
The dendritic spines of the MSNs of the NAc were significantly different as a
population in the HIV-1 Tg animals compared to controls, thus providing
evidence the mesocorticolimbic pathway is altered in the HIV-1 Tg animals,
which may be due to RhoA upregulation by the Tat protein which is essential for
motivated behaviors.
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Furthermore, AMPA/NMDA receptors are formed during plasticitydependent alterations in the MSNs of the NAc. Activation of the AMPA receptor
in glutamatergic synapses (such as MSNs) is required in long-term potentiation
(LTP). Both AMPA and NMDA receptors are able to bind glutamate in normal
tonic activation and allow Na+ to flow inside of the postsynaptic membrane
through the AMPA receptor exclusively. Such is the case during low-frequency
EPSPs(i.e. weak stimulation) from the presynaptic neuron. Na+ only flows
through the AMPA receptor, as the NMDA receptor has a Mg2+ molecule resting
within the NMDA channel. During high-frequency EPSPs, the voltage-gated
NMDA channel changes confirmation, and forces the Mg2+ block out of the
channel to allow Na+ and Ca++ to flow into the postsynaptic neuron. The influx of
Ca++ initiates intracelluar signaling cascades such as Ca2+/calmodulin-dependent
protein kinase (CaMKII) and protein kinase C (PKC) which induces LTP.
Continuous low-frequency EPSPs cause a slow, steady increase in Ca++ in the
postsynaptic neuron, which leads to long-term depression (LTD) which reduces
the synaptic contacts and reduces the number of AMPA receptors. Alternatively,
fast and large increases in Ca++ promote increased AMPA receptor expression
and strengthen synaptic connections. During LTP the sensitivity of the
postsynaptic cell to glutamate is increased through expression of additional
AMPA receptors. Which thereby increase the ability of higher frequency EPSPs
to remove the Mg2+ block from the NMDA receptor, thus yielding a strengthening
of the synapse (Purves et al., 2012c). Alterations in synaptic
creation/modification (dendritic spines) from HIV-1 viral proteins may therefore
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affect the efficacy of rewarding stimuli. In the current study, the histological data
suggests the differences found in a naturally rewarding behavior (wheel running)
may be a product of synaptic alterations and reduced plasticity-dependent
efficiency. Previous studies have shown HIV-1 Tat is able to interact with the
NMDA receptors of the hippocampus and produce learning deficiencies (Self,
Smith, Butler, Pauly, & Prendergast, 2009), thus it is possible alterations in
motivation may be created by altered MSN plasticity.
Ovariectomized females were chosen for the current study because
worldwide, HIV-1 infection afflicts women slightly more than men, comprising
~51% of all cases (World Health Organization, 2015), and women are at an
increased risk for neurocognitive deficits compared to men (Chiesi et al., 1996).
Furthermore, women are underrepresented in the scientific literature in
neuropsychological studies where most studies contain only male subjects or
male rats (Fox-Tierney, Ickovics, Cerreta, & Ethier, 1999). The animals were
ovariectomized, as wheel running follows an estrus cycle-dependent pattern
(Anantharaman-Barr & Decombaz, 1989) in intact female rats. Additionally, it has
been shown at least in cell cultures that 17β-estradiol is capable of reducing
apoptosis from the HIV-1 Tat protein (Adams, Aksenova, Aksenov, Mactutus, &
Booze, 2010). Collectively, these studies warrant the examination of HIV-1
neuroprogression in ovariectomized female animals in the current study.
Outside of dendritic spine alterations in the HIV-1 Tg rat, decreased
running activity may also be due to decreased dopamine efficiency in the HIV-1
Tg animal, based on previous work which examined the dopaminergic
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projections from the VTA and NAc (Greenwood et al., 2011; Mogenson et al.,
1979; Mogenson & Yang, 1991; Pijnenburg et al., 1976; Roberts et al., 2012) and
their necessity for motivated behaviors such as area exploration and wheel
running. The reduction in dopaminergic efficiency may be caused by DAT
dysregulation which is found in the HIV-1 Tg rat (McIntosh et al., 2015; Midde et
al., 2012) as well as in HIV-1 seropositive humans (Chang et al., 2008; Wang et
al., 2004). The DAT is directly affected by the HIV-1 protein Tat (Midde et al.,
2012; Midde et al., 2013; Yuan et al., 2015; Zhu, Mactutus, Wallace, & Booze,
2009). Deficits in the DAT would produce behavioral alterations in motivated
behaviors which require dopaminergic activation, such as wheel running and
area exploration. The HIV-1 Tg rat ran lower distances and produced fewer
running bouts as a population compared to controls as shown by the data, which
is indicative of mesocorticolimbic dopaminergic dysregulation. This hypothesis is
supported by the histological findings of the NAc MSN spine alterations.
Additionally, the motivational efficacy for wheel running was not altered in the
HIV-1 Tg rat compared to F344 controls as shown by the results of the
Deprivation/Response data, as both groups escalated their running distances in
response to the deprivation of the running wheel, albeit at slightly different rates.
Running is a rewarding activity, as shown by the deprivation/response trials, as
both groups of animals increased their running activity compared to previously
stabilized levels. An increase in responding is indicative of mesocorticolimbic
activity (Basso & Morrell, 2015; Mogenson et al., 1979; Mogenson & Yang, 1991;
Pijnenburg et al., 1976) regarding a rewarding stimulus. Interestingly, the HIV-1
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Tg animals took 2 days of deprivation to produce the equivalent increase in
running distances compared to controls.
Significant differences in body weight was shown in the HIV-1 Tg animals,
similar to previous studies (June et al., 2009; Midde et al., 2011; Moran et al.,
2013). The animals weighed significantly less as a group, but importantly, grew
at the same rates (not significant Day*Genotype interaction). The body weight
analysis suggests the HIV-1 Tg animals are as healthy as controls in their
physiological development, and therefore are physiologically capable of running
distances equal to age-matched F344 controls. To verify, maximal running speed
attained in each group was compared. As the HIV-1 Tg animals are significantly
smaller, it is reasonable to theorize they lacked the capacity for running as fast
as their control counterparts based on physiological demands, and perhaps is the
reason for the differential distance findings. However, the groups were not
significantly different in their maximal running speed attained was shown in the
Maximal Speed data. Additionally, previous findings (June et al., 2009; Midde et
al., 2011; Moran et al., 2013) in the HIV-1 Tg rat regarding motivational deficits in
the open-field activity chambers when tested during the diurnal phase of their
circadian cycle; as well as altered rates of habituation in all aspects of general
motility (gross movements, fine movements, and rearing) was replicated in the
current study. The groups showed significantly different rates of habituation in the
activity chambers as assessed by the significant genotype × bin interaction. It
may be argued the differences in locomotor activity were a behavioral
manifestation of apathy in the HIV-1 Tg rat.
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However, there are several caveats one must remember when interpreting
the results. Primarily, only the motivational properties of the HIV-1 Tg rat was
examined, and therefore the interpretation to human seropositive individuals and
motivational parallels must be cautious. Secondly, the HIV-1 Tg rat is a
genetically altered vehicle for HIV-1 study, created through embryonic
alterations, and does not provide information identical to that found in HIV-1
seropositive human subjects, nor does it allow the examination of the fully
functioning (9 of 9 genes expressed) HIV-1 virus. Third, the current study only
examined a motivated behavior during 1 hour in a 24-hour cycle; what occurred
outside of testing hours remains to be determined. However, extrapolation of
overall daily activity can be determined through examinations of optimal one-hour
testing (Shirley M., 1928a). Finally, caution must be used when interpreting the
results to intact females and males as ovariectomized females were utilized in
the current study.
In summary the data argue the HIV-1 Tg rat is a potential candidate to
examine the motivational deficiencies found in the human HIV-1+ populations,
specifically reduced motivation for a naturally rewarding behavior (such as
medication adherence). Additionally, a potential mechanism for the reduction in
motivation: MSN dendritic spine alterations potentially through upregulation of
RhoA signalling by the Tat protein has been suggested. Potential therapeutics
can utilize the HIV-1 Tg rat model to establish pharmaceutical therapies to
combat the apathy problem in the HIV-1+ human population by creating
therapies capable of protecting or restoring the MSNs of the nucleus accumbens.
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Reductions of apathy prevalence in the HIV-1 populations may increase
medication adherence; thus preventing viral rebound and medication resistance,
and improve individual state of mind; with less depressive qualities and improved
outlook, collectively resulting in a healthier afflicted individual overall.
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